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Cancer Stem Cell and Bulk Cancer Cell Active Copper(II) 
Complexes with Vanillin Schiff Base Derivatives and Naproxen 
Chunxin Lu,[a] Arvin Eskandari,[a] Paul B. Cressey,[a] and Kogularamanan Suntharalingam*[a] 
Dedication ((optional)) 
Abstract: Four copper(II) complexes, 1-4 containing regioisomeric 
vanillin Schiff base derivatives ((E)-5/4/3/2-methoxy-2-(((2-
(methylthio)ethyl)imino)methyl)phenol) and the nonsteroidal anti-
inflammatory drug (NSAID), naproxen, were synthesised and 
characterised. All complexes effectively cleave DNA in cell-free 
systems, with 4 displaying the highest nuclease activity. DNA 
binding studies suggest that 4 binds to DNA via the grooves prior to 
inducing oxidative DNA cleavage. Three of the complexes (1, 3, and 
4) indiscriminately kill cancer stem cell (CSC)-enriched cells 
(HMLER-shEcad) and bulk cancer cells (HMLER) at micromolar 
concentrations. The most effective complex, 4 also reduced the 
formation and size of mammospheres to a similar extent as 
salinomycin, a well-established CSC-potent agent. Mechanistic 
studies show that 4 is readily taken up by CSCs, elevates 
intracellular reactive oxygen species (ROS) levels, causes DNA 
damage, and induces caspase-dependent apoptosis. Furthermore, 4 
inhibits cyclooxygenase-2 (COX-2) expression and causes COX-2-
dependent CSC death. The advantage of 4 over bulk cancer cell- or 
CSC-selective agents is that it has the potential to remove whole 
tumor populations (bulk cancer cells and CSCs) with a single dose. 
Tumors are made up of complex heterogenous cancer cell 
populations with hierarchical organization.[1] Cancer stem cells 
(CSCs) are a small, biological distinct subset within the total 
malignant cell population perched atop the tumor hierarchy.[2] 
Like normal stem cell, CSCs are immortal or long-lived and thus 
have the potential to accumulate the necessary mutations for 
malignant transformation and subsequent tumor initiation.[3] 
CSCs are also linked to metastasis due to their unlimited tumor-
initiating potential and inherent plasticity to survive secondary 
tumor sites.[4] Given the evolutionary predisposition of stem cells 
to survive harsh conditions, CSCs can escape attack from 
current chemotherapeutic and radiation regimens (at their 
therapeutically administered doses).[5] Several mechanisms 
potentially contribute to CSC chemo- and radio-resistance, these 
include; overexpression of quiescence CSCs that can evade 
treatments targeting proliferative cells, overactivation of multiple 
developmental signalling pathways, upregulation of anti-
apoptotic proteins combined with the downregulation of pro-
apoptotic machinery, and increased capacity for DNA repair.[6] 
The clinical implication of CSCs is that elimination of entire 
tumor populations, including CSCs, is necessary for long-lasting 
outcomes, and the failure to do so leaves open the possibility of 
cancer reoccurrence. Although a great amount of time has been 
devoted to identifying CSC therapeutic targets such as cell 
surface markers, organelles, dysregulated signalling pathways, 
and components of their microenvironment,[7] there is still no 
clinically approved agent (chemical or biological) that can 
simultaneously remove bulk cancer cells and CSCs. The 
development of CSC-potent agents is in its early stage and most 
of the drug candidates undergoing pre-clinical or clinical trials 
are completely organic in nature. We and others have recently 
shown that metal-containing compounds are also capable of 
potently killing CSCs and bulk cancer cells.[8]  
CSCs maintain relatively low levels of reactive oxygen 
species (ROS) compared to bulk cancer cells.[9] The low ROS 
concentration in CSCs is associated to increased expression of 
free radical scavenging systems. This protects CSCs from 
biomolecule damage and contributes to chemo- and radio-
resistance. As CSCs have adapted to thrive in ROS-deficient 
conditions, the intracellular redox state in CSCs is thought to be 
finely regulated. Therefore, the application of ROS-inducer, in 
tandem with CSC-targeted therapies, represents a potentially 
efficacious strategy for eradicating CSCs. Using this approach, 
we previously developed a series of copper(II)-phenanthroline 
complexes containing the nonsteroidal anti-inflammatory drugs 
(NSAID); indomethacin, naproxen, and tolfenamic acid, capable 
of selectivity killing breast CSCs over bulk breast cancer 
cells.[8b,8e] The copper(II)-phenanthroline-NSAIDs complexes 
induced CSC death by increasing intracellular ROS levels and 
inhibiting cyclooxygenase-2 (COX-2), an enzyme that catalyzes 
the rate-limiting step of prostaglandin biosynthesis (from 
arachidonic acid). COX-2 is involved in inflammatory response, 
linked to cancer progression and dissemination, and promotes 
stem cell renewal and proliferation.[10]  
As CSC-specific agents only target a small subpopulation 
of tumor cells, they cannot rapidly reduce tumor mass when 
administered alone.[11] Thus, CSC-specific agents cannot 
provide the short term, measurable readout typically required for 
successful clinical trials. Removing CSCs using CSC-specific 
agents will, however, inhibit tumor growth over the longer term 
as CSCs will no longer be present to replenish the bulk tumor 
population.[11] Given the current methodologies used to evaluate 
the clinical efficacy of anticancer therapies, the most effective 
and measurable cancer treatments (in the short and long term) 
are those that can concurrently reduce tumor bulk and kill CSCs. 
Here, we present a series copper(II) complexes with 
regioisomeric vanillin Schiff base derivatives and naproxen, 1-4. 
Three of the complexes (1, 3, and 4) effective kill CSCs and bulk 
cancer cells within a small concentration window. The 
mechanism of action of the most effective complex in the series, 
4 is described in detail. Schiff base copper(II) complexes are 
well-known ROS generators capable of inducing apoptosis in 
various cancer cells by DNA damage or mitochondrial 
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dysfunction,[12] however, there have been no reports on their 
CSC activity. 
Results and Discussion 
Synthesis and Characterization 
The copper(II) complexes, 1-4 were synthesized as outlined in 
Scheme 1. The vanillin Schiff base ligands, L1-4 were prepared 
by refluxing equimolar amounts of 2-(methylthio)ethan-1-amine 
with the appropriate 2-hydroxy-methoxybenzaldehyde in ethanol 
for 16 h. The ligands, L1-4 were isolated in good yields (90-95%) 
as yellow oils and fully characterized by 1H and 13C NMR, 
infrared spectroscopy, and API-MS mass spectrometry (see 
ESI). Characteristic signals at 8.23-8.83 ppm in the 1H NMR 
spectra and C=N bands at 1622-1641 cm-1 in the IR spectra for 
L1-4 confirmed formation of the imine functionality. 
Disappearance for the aldehyde peak (ca. 9.90 ppm) associated 
to the various 2-hydroxy-methoxybenzaldehyde starting 
materials established full conversion. The copper(II) complexes, 
1-4 were prepared by refluxing L1-4 with Cu(NO3)2·3H2O and 
naproxen in ethanol (pH 7, adjusted by triethylamine) for 24 h. 
The complexes were isolated in reasonable yields (20-67%) as 
green solids and characterized by high-resolution ESI-TOF 
mass spectrometry, infrared spectroscopy, and elemental 
analysis (see ESI). Distinctive molecular ion peaks 
corresponding to the reduced forms of 1-4 with the appropriate 
isotopic pattern were observed in the ESI-TOF mass spectra 
(m/z = 519.0647 a.m.u, [reduced 1+H]+; 519.0680 a.m.u. 
[reduced 2+H]+; 519.0668 a.m.u. [reduced 3+H]+; 519.0692 
a.m.u. [reduced 4+H]+) (Figure S1-4). The IR spectra for 1-4 
displayed νasym(CO2) and νsym(CO2) stretching bands at 1602-
1609 cm-1 and 1384-1397 cm-1, respectively (Figure S5). The 
difference, Δ, between the νasym(CO2) and νsym(CO2) stretching 
bands for 1-4 varied between 205-225 cm-1, suggestive of an 
unidentate coordination mode for the carboxylate moiety on 
naproxen to the copper center.[13] This assignment is consistent 
with that reported for other copper(II) complexes bearing 
tridentate Schiff bases and carboxylic acid-containing ligands.[14] 
The purity of 1-4 was established by elemental analysis. 
 
Scheme 1. The reaction scheme for the preparation of the vanillin Schiff base 
ligands, L1-4 and the corresponding copper(II) complexes, 1-4. 
 
DNA Cleavage and Binding Studies 
Several Schiff base copper(II) complexes have been reported to 
bind and cleave double stranded DNA.[12] The DNA nuclease 
activity of 1-4 was assessed by agarose gel electrophoresis. 
Upon incubation of plasmid pUC19 DNA (100 ng) with 1-4 (0–50 
µM for 24 h in the absence of external reducing agents), a 
marked decrease in the amount of supercoiled DNA (form I) and 
a concurrent increase in the amount of nicked circular DNA 
(form II) was observed, indicative of DNA cleavage (Figure 1A 
and S6). Complexes 2 and 4 displayed the highest nuclease 
activity with complete conversion of supercoiled to nicked 
circular DNA occurring at 10 µM. In the presence of ascorbic 
acid, 4 induced complete conversion of supercoiled DNA (form I) 
to circular and linear DNA (form II/III) at 10 µM, and cleavage 
into several small fragments at higher concentrations (25-50 µM) 
(Figure 1B). The enhanced nuclease activity of 4 in the presence 
of ascorbic acid, suggests that 4-mediated DNA cleavage is 
redox-dependent. To determine the oxidative mechanism by 
which 4 induces DNA cleavage, nuclease activity was probed in 
the presence of reactive oxygen species (ROS) scavengers 
(NaN3, KI, DMSO, and tBuOH) (Figure 1C). KI and NaN3 
displayed the greatest inhibitory effect, suggesting that hydrogen 
peroxide (H2O2) and singlet oxygen (1O2) are the major ROS 
intermediates formed during the DNA cleavage process. We 
propose that the copper(II) complex undergoes reduction to the 
corresponding copper(I) form by guanine bases in pUC19 DNA. 
The copper(I) form then reduces molecular oxygen to 
superoxide, which generates hydrogen peroxide.[15] The 
paramagnetic copper(II) form and the naproxen moiety could be 
responsible for singlet oxygen generation, via a photo-redox 
pathway in ambient light.[14b,16] To shed light on the DNA-binding 
mode of 4 prior to initiating DNA cleavage, the nuclease activity 
was probed in the presence of a minor groove binder (DAPI, 2-
(4-amidinophenyl)-1H-indole-6-carboxamidine, 50 µM) and a 
major groove binder (methyl green, 50 µM). DNA cleavage was 
inhibited in the presence of methyl green and DAPI, suggesting 
that 4 binds to both the minor and major DNA grooves (Figure 
1D). 
To elucidate the binding affinity and further investigate the 
binding mode of 4 to duplex DNA, UV-Vis spectroscopic 
titrations were performed.  Upon addition of aliquots of calf 
thymus DNA (ct-DNA), in the mM range, to a solution of 4 (50 
µM), significant spectral changes were observed (Figure 1E). 
The absorption band corresponding to the metal perturbed intra-
ligand π-π* transition (298 nm) displayed hypochromicity (20.0 ± 
0.2 %), and bathochromicity (10.0 ± 0.6 nm). Three sharp 
isosbestic points were also noted. These features are 
characteristic of interactions with DNA bases, either by 
intercalation or groove binding. From the absorbance, the 
concentration of bound and unbound 4 was calculated and 
extrapolated to determine the binding constant (see ESI, Figure 
S7).[17] The intrinsic binding affinity of 4 to ct-DNA was calculated 
to be 1.3 ± 0.3 × 105 M-1. This value is 1 to 2 orders of 
magnitude lower than those reported for strong 
metallointercalators,[18] suggesting that a non-intercalative 
binding interaction could be operative.  
To examine the binding mode of 4 to DNA further, DAPI 
and ethidium bromide (a strong intercalator) displacement 
studies were performed. Upon incremental addition of 4 (0 - 200 
µM) to a solution of ct-DNA (20 µM) and DAPI (1 µM), the 
emission associated to the DAPI-DNA complex (originating from 
the binding of DAPI to the minor groove) markedly decreased 
(Figure S8). In contrast, upon incremental addition of 4 (0 - 200 
µM) to a solution of ct-DNA (20 µM) and ethidium bromide (1 
µM), the emission associated to the ethidium bromide-DNA 
complex (originating from the intercalation of ethidium bromide 
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between DNA base pairs) was largely unaltered (Figure S9). 
This suggests that 4 preferentially binds to the DNA grooves 
(over intercalation). Control studies with naproxen and L4 
revealed that naproxen (0 - 200 µM) does not effectively 
displace DAPI from ct-DNA (Figure S10), whereas L4 (0 - 200 
µM) displaces DAPI to a similar extent as 4 (Figure S11), 
suggesting that the groove binding ability of 4 is facilitated by the 
L4 moiety. Collectively, the DNA cleavage, UV-Vis titration and 
dye displacement studies suggest that 4 binds to DNA via the 
grooves prior to inducing oxidative DNA cleavage.  
 
 
 
Figure 1. (A) Concentration-dependent DNA cleavage by 4 after 24 h 
incubation, Lane 1: DNA only, Lane 2-4: DNA + 10, 25, and 50 μM of 4. (B) 
Effect of ascorbic acid on 4-mediated DNA cleavage after 24 h incubation, 
Lane 1: DNA only, Lane 2-4: DNA + 10, 25, and 50 μM of 4 with 10 
equivalents of ascorbic acid. (C) Inhibition of 4-mediated DNA cleavage by 
ROS scavengers after 24 h incubation. a)  Lane 1: DNA only, Lane 2: DNA + 4 
(10 μM), Lane 3-6: DNA + 4 (10 μM) + NaN3 (40 mM), KI (40 mM), DMSO (10 
mM), or tBuOH (10 mM). (D) Inhibition of 4-mediated DNA cleavage by DNA 
minor and major groove binders after 24 h incubation, Lane 1: DNA only, Lane 
2: DNA + 4 (10 μM), Lane 3: DNA + 4 (10 μM) + methyl green (50 μM), Lane 
4: DNA + 4 (10 μM) + DAPI (50 μM). (E) Representative UV-Vis trace of 4 (50 
µM) upon addition of ct-DNA (0 - 0.9 equivalence). 
 
Lipophilicity and Stability in Biologically Relevant Solutions 
The lipophilicity of 1-4 was determined by measuring the extent 
to which it partitioned between octanol and water, P. The 
experimentally determined Log P values varied from -0.200 ± 
0.011 to -0.093 ± 0.015 (Table S1). The position of the methoxy 
group appears to subtly affect lipophilicity, with hydrophobicity 
increasing in the following order; 4 > 3 > 1 > 2. The amphiphilic 
nature of 1-4 suggests that the copper(II) complexes should be 
readily taken up by cells and soluble in aqueous solutions. UV-
Vis spectroscopy studies were carried out to assess the stability 
of 4, taken as a representative member of the copper(II) 
complexes, in biological relevant solutions. In PBS, 4 (50 µM) is 
reasonably stable over the course of 24 h at 37 oC (Figure S12). 
In the presence of ascorbic acid or glutathione (10 equivalents in 
PBS), the absorption of 4 (50 µM) changed dramatically over the 
course of 24 h at 37 oC, yielding spectra reminiscent of free 
naproxen (Figure S13-15). Upon incubation of concentrated 
PBS:DMSO (95:5) solutions of 4 (250 µM) with ascorbic acid or 
glutathione (10 equivalence in PBS) for 24h at 37 oC, the d-d 
transition band (637 nm) associated to the copper(II) center 
decreased markedly suggesting reduction to copper(I) (Figure 
S16-17). This was further evidenced by adding bathocuproine 
disulfonate (BCS, 2 equivalence), a strong copper(I) chelator, 
which produced a characteristic absorption band at 480 nm 
corresponding to [CuI(BCS)2]3- (Figure S18-19).[19] Taken 
together, the UV-Vis stability studies suggest that 4 is reduced 
from the Cu(II) to Cu(I) form under reducing conditions and that 
this facilitates the release of naproxen.  
 
Bulk Cancer and Cancer Stem Cell Potency 
To determine the CSC and non-CSC potency of 1-4, two human 
mammary epithelial cell lines (HMLER and HMLER-shEcad 
cells) were used. HMLER cells contain a stable CSC-like 
population of 5-8% and HMLER-shEcad cells express a ca. 90% 
CSC-like population.[20] The cytotoxicity of 1-4 towards HMLER 
and HMLER-shEcad cells was measured using the MTT [3-(4,5-
di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay 
after 72 h incubation. IC50 values (concentrations required to 
induce 50% cell death) were determined from dose–response 
curves (Figure S20-23) and are summarized in Table 1. Three of 
the complexes (1, 3, and 4) displayed micromolar potency 
towards CSC-enriched HMLER-shEcad cells and CSC-depleted 
HMLER cells. Notably, 4 is the most potent complex within the 
series.  Unlike salinomycin, a “gold standard” CSC-selective 
agent[20] and the CSC-selective copper(II)-phenanthroline-
NSAID complexes recently reported by our group,[8b,8e] 4 
indiscriminately kills CSCs and bulk cancer cells. Therefore, 4 
has the potential to remove cancer cell populations in their 
entirety (bulk cancer cells and CSCs) with a single dose. The 
trend between the position of the methoxy group and lipophilicity 
(noted previously) is loosely observed for potency against bulk 
cancer (HMLER) and CSCs (HMLER-shEcad). The L2-bearing 
complex, 2 was the most hydrophilic within the series and the 
least cytotoxic towards bulk cancer cells and CSCs (>100 μM). 
As a measure of therapeutic potential, we conducted cytotoxicity 
studies with normal human ﬁbroblast GM05757 cells (Figure 
S24 and Table S2). In general, 1-4 displayed similar potency for 
GM05757 cells as bulk cancer and CSCs. Only complex 4 
displayed lower potency (2-fold) for the normal ﬁbroblast cell line 
than for the cancer cell lines. 
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Table 1. IC50 values of the copper(II) complexes, 1-4 and salinomycin 
against HMLER and HMLER-shEcad cells. 
Compound HMLER IC50 [μM][a] HMLER-shEcad IC50 [μM][a] 
1 61.0 ± 0.9 56.8 ± 3.1 
2 > 100 > 100 
3 61.5 ± 2.2 67.4 ± 4.7 
4 37.6 ± 3.3 36.0 ± 4.6 
salinomycin[b] 11.4 ± 0.42 4.2 ± 0.4 
[a] Determined after 72 h incubation (mean of three independent 
experiments ± SD). [b] Taken from reference 8b. 
Inhibition of Mammosphere Formation 
Breast CSCs cultured in anchorage-independent, serum-free 
conditions, over extended periods of time, form three-
dimensional, tumor-like structures called mammospheres.[21] The 
capacity of a given agent to inhibit mammosphere formation 
from single cell suspensions provides a reliable marker for CSC 
potency. The ability of 1-4 to inhibit mammosphere formation 
was assessed using an inverted microscope. Treatment with 1-3 
(at the IC20 value after 5 days of incubation) did not significantly 
affect the number or size of mammospheres formed (p = 0.08 for 
1, p = 0.35 for 2, and p = 0.31 for 3) (Figure 2). The addition of 4 
(at the IC20 value after 5 days of incubation) significantly reduced 
the number of mammospheres formed (38%, p < 0.05).  The 
size of mammospheres formed was also markedly reduced upon 
incubation with 4 (Figure 2). The number and size of 
mammospheres formed decreased to a slightly better extent 
upon treatment with salinonmycin (at the IC20 value after 5 days 
of incubation) (Figure 2).  
 
 
 
Figure 2. (A) Quantification of mammosphere formation with HMLER-shEcad 
cells untreated and treated with 1-4 and salinomycin at their respective IC20 
values for 5 days. Error bars = SD and Student t-test, * = p < 0.05. (B) 
Representative bright-field images (× 10) of the mammospheres in the 
absence and presence of 1-4 and salinomycin at their respective IC20 values. 
Cellular Mechanism of Action 
Cell uptake studies were performed to determine the CSC 
permeability of 1-4. Specifically, HMLER-shEcad cells were 
incubated with 1-4 at a non-lethal dose (10 µM for 24 h) and the 
copper content was determined by inductively coupled plasma 
mass spectrometry (ICP-MS). As shown in Figure S25, all the 
complexes were taken up readily by HMLER-shEacd cells, with 
whole cell uptake ranging from 81.2 ± 1.7 ppb of Cu/ million cells 
for 3 to 336.8 ± 8.0 ppb of Cu/ million cells for 1. No correlation 
was noted between whole cell uptake and cytotoxicity of 1-4. For 
the most effective complex, 4, fractionation studies were carried 
to determine cell localization (Figure 3A). A substantial amount 
of internalized 4 (25%) was found in the nucleus, providing 
assess to genomic DNA. This may be attributed to the naproxen 
moiety, which is known to target COX-2 localized on the nuclear 
envelop.[22] An appreciated amount of internalized 4 was also 
observed in the cytoplasm (57%). Taken together, the 
fractionation studies suggest that 4-induced cell toxicity could be 
related to genomic DNA-dependent or -independent 
mechanisms. 
Copper(II) complexes bearing Schiff base ligands are 
known to induce cell death by elevating intracellular ROS 
levels.[12] To investigate if 4-indued toxicity is related to ROS 
production, intracellular ROS levels were quantified at different 
exposure times using 6-carboxy-2’,7’-dichlorodihydrofluorescein 
diacetate (DCFH-DA), a well-established ROS indicator. Upon 
incubation of HMLER-shEcad cells with 4 (50 µM) for 6 h a 
marked increase (27%) in intracellular ROS levels was observed 
compared to the untreated control cells (Figure S26). Exposure 
of 4 (50 µM) for longer periods (12 and 24 h) did not result in 
ROS increase relative to untreated cells, suggesting that 4-
mediated ROS generation is time-dependent (Figure S26). 
Similar time-dependent ROS production properties have been 
reported for other metal complexes.[23] H2O2-treated (150 µM for 
6, 12, and 24 h) HMLER-shEcad cells exhibited a significant 
increase (p < 0.01) in ROS levels (Figure S27). Both 4- (after 6 h 
exposure) and H2O2- (after 6, 12, and 24 h exposure) induced 
ROS production was attenuated in the presence of N-
acetylcysteine (2.5 mM), a ROS scavenger (Figure S26-27). 
Overall, this suggests that 4-induced cell death could be 
associated to intracellular ROS generation.  
As 4 was found to increase intracellular ROS levels, enter 
the nucleus, and displays redox-mediated nuclease activity in 
cell-free systems, immunoblotting studies were carried out to 
determine if 4 induces DNA damage in CSCs. HMLER-shEcad 
cells dosed with 4 (5-20 µM for 72 h) exhibited a marked 
increase in the expression of phosphorylated H2AX (γH2AX) 
and a slight increase in the expression of phosphorylated CHK2, 
implicative of DNA damage (Figure S28).[24] DNA damage, when 
left unrepaired, can lead to apoptosis,[25] therefore the 
expression of proteins associated to apoptosis were monitored. 
HMLER-shEcad cells treated with 4 (5-20 µM for 72 h) exhibited 
a clear increase in the level of cleaved caspase 3 and 7 
compared to untreated control cells, indicative of caspase-
dependent apoptosis (Figure S28). Collectively, the 
immunoblotting studies show that 4 induces DNA damage and 
apoptotic CSC death.  
Elevated levels of COX-2 have been linked to poor 
prognostic markers in cancer patients such as high tumor grade 
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and large tumor size.[26] Further, COX-2 is implicated in CSC 
regulation and thought to promote CSC-like properties such as 
stemness, tumorosphere formation, and metastatic 
propensity.[27] As complex 4 contains a naproxen moiety, an 
established COX-2 inhibitor, flow cytometric studies were 
conducted to determine if the mechanism of action of 4 involved 
COX-2 inhibition. HMLER-shEcad cells pre-treated with 
lipopolysaccharide (LPS) (5 μM for 24 h), to increase basal 
COX-2 levels, and dosed with 4 (12.5-50 μM for 48 h) displayed 
a noticeable decrease in COX-2 expression compared to 
untreated cells (Figure 3B). A similar decrease in COX-2 
expression was also noted for naproxen-treated (20 μM for 48 h) 
HMLER-shEcad cells (Figure S29). This suggests that the 
cytotoxic effect of 4 may involve COX-2 downregulation. To 
determine if 4 induces COX-2 dependent CSC death, 
cytotoxicity studies were performed with HMLER-shEcad in the 
presence and absence of prostaglandin E2 (PGE2) (20 μM, 72 
h), the functional product of COX-2-mediated arachidonic acid 
metabolism. The potency of 4 towards HMLER-shEcad cells 
decreased significantly in the presence of PGE2 (Figure 3C), 
suggesting that 4 induces COX-2-dependent CSC death. 
 
Figure 3. (A) Copper content in whole cell, cytoplasm, and nucleus fractions 
isolated from HMLER-shEcad cells treated with 4 (10 µM for 24 h). (B) 
Representative histograms displaying the green fluorescence emitted by anti-
COX-2 Alexa Fluor 488 nm antibody-stained HMLER-shEcad cells treated with 
LPS (2.5 μM) for 24 h (red) followed by 48 h in media containing 4 (12.5 - 50 
μM, blue, orange, and green). (C) Representative dose-response curves for 
the treatment of HMLER-shEcad cells with 4 after 72 incubation in the 
presence and absence of PGE2 (20 μM). 
Conclusion 
In summary, we report four new copper(II) complexes with 
vanillin Schiff base derivatives and naproxen. DNA cleavage and 
binding studies suggest that the most effective complex, 4 binds 
to DNA via the grooves (1.3 ± 0.3 × 105 M-1) and induces 
oxidative cleavage (at 10 µM). Hydrogen peroxide (H2O2) and 
singlet oxygen (1O2) were identified to be the main ROS 
intermediates formed during the DNA cleavage process. 
Complex 4 was found to kill bulk breast cancer cells and breast 
CSCs with micromolar toxicity (37.6 ± 3.3 and 36.0 ± 4.6 µM 
respectively), and potently inhibit mammosphere formation (38% 
decrease upon treatment at IC20 value for 5 days) to a similar 
extent as salinomycin. Given that several copper(II) complexes 
reported in literature are known to cleave DNA and exhibit 
toxicity in the micromolar range, the true anticancer potential of 
these compounds need to be determined using in vivo cancer 
models. We are in the process of initiating in vivo studies in mice 
with 4. Mechanistic studies suggest that 4 increases intracellular 
ROS levels at short exposure times (6 h), damages DNA, 
downregulates COX-2 expression, and triggers caspase-
dependent apoptosis. As 4 displays equal potency towards bulk 
cancer cells and CSCs, it could potentially remove entire cancer 
populations with a single dose. This study not only shows that 
copper(II) complexes with vanillin Schiff base derivatives and 
NSAIDs warrant further investigation as anticancer agents 
capable of eliminating heterogenous tumor populations, but it 
also provides insight into copper-induced cell death. 
Experimental Section 
Materials and Methods 
 
All synthetic procedures were performed under normal atmospheric 
conditions. Fourier transform infrared (FTIR) spectra were recorded with 
a IRAffinity-1S Shimadzu spectrophotometer. High resolution electron 
spray ionisation mass spectra were recorded on a BrukerDaltronics 
Esquire 3000 spectrometer by Dr. Lisa Haigh (Imperial College London). 
UV-Vis absorption spectra were recorded on a Cary100 UV-Vis 
spectrophotometer. Elemental analysis of the compounds prepared was 
performed commercially by London Metropolitan University. 2-
(Methylthio)ethan-1-amine, 2-hydroxy-3-methoxybenzaldehyde, 2-
hydroxy-4-methoxybenzaldehyde, 2-hydroxy-5-methoxybenzoic acid, and 
2-hydroxy-6-methoxybenzaldehyde were purchased from Sigma Aldrich 
and used as received. For the high concentration UV studies (250 µM), a 
10 mM stock solution of 4 in DMSO was initially prepared. The copper 
concentration of the stock solution was determined by inductively 
coupled plasma mass spectrometry (ICP-MS, PerkinElmer NexION 
350D). The stock solution was diluted in PBS to the working 
concentration.  
 
Synthesis 
 
(E)-2-methoxy-6-(((2-(methylthio)ethyl)imino)methyl)phenol (L1): A 
mixture of 2-(methylthio)ethan-1-amine (91 mg, 1 mmol) and 2-hydroxy-
3-methoxybenzaldehyde (152 mg, 1 mmol) were refluxed in ethanol (20 
mL) for 16 h. The reaction mixture was then evaporated under vacuum to 
afford a yellow oil. Yield: 207 mg (92%). 1H NMR (400 MHz, CDCl3): δ 
13.69 (s, 1H), 8.37 (s, 1H), 6.94-6.89 (m, 2H), 6.82 (t, 1H), 3.91(s, 3H), 
3.82 (t, 2H), 2.83 (t, 2H), 2.14 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 
165.9, 151.7, 148.5, 123.0, 118.5, 118.0, 114.1, 58.9, 56.1, 35.1, 16.1. IR 
(solid, cm-1): 1631, 1462, 1249, 1080, 1049, 965, 839, 779, 733. API-MS 
(positive) m/z: 226.2 [M+H]+; (negative) m/z: 224.2 [M-H]
－
. 
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(E)-5-methoxy-2-(((2-(methylthio)ethyl)imino)methyl)phenol (L2): A 
mixture of 2-(methylthio)ethan-1-amine (91 mg, 1 mmol) and 2-hydroxy-
4-methoxybenzaldehyde (152 mg, 1 mmol) were refluxed in ethanol (20 
mL) for 16 h. The reaction mixture was then evaporated under vacuum to 
afford a yellow solid. Yield: 202 mg (90%). 1H NMR (400 MHz, CDCl3): δ 
13.75 (s, 1H), 8.23 (s, 1H), 7.13 (d, 1H), 6.44-6.39 (m, 2H), 3.81(s, 3H), 
3.75 (t, 2H), 2.81 (t, 2H), 2.14 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 
165.1, 164.7, 163.6, 132.7, 112.3, 106.5, 101.2, 57.9, 55.9, 36.2, 16.0. IR 
(solid, cm-1): 1641, 1611, 1513, 1481, 1440, 1362, 1328, 1269, 1217, 
1170, 1111, 1011, 969, 895, 842, 788, 760, 668, 569, 512. API-MS 
(positive) m/z: 226.2 [M+H]+, 258.1 [M+CH3OH+H]+. 
 
(E)-4-methoxy-2-(((2-(methylthio)ethyl)imino)methyl)phenol (L3): A 
mixture of 2-(methylthio)ethan-1-amine (91 mg, 1 mmol) and 2-hydroxy-
5-methoxybenzoic acid (152 mg, 1 mmol) were refluxed in ethanol (20 
mL) for 16 h. The reaction mixture was then evaporated under vacuum to 
afford a yellow oil. Yield: 211 mg (94%). 1H NMR (400 MHz, CDCl3): δ 
12.75 (s, 1H), 8.34 (s, 1H), 6.95-6.89 (m, 2H), 6.79 (d, 1H), 3.81 (t, 2H), 
3.78 (s, 3H), 2.83 (t, 2H), 2.14 (s, 3H). 13C NMR (100 MHz, CDCl3): δ 
165.6, 155.2, 152.0, 119.4, 118.3, 117.8, 114.9, 59.2, 55.9, 36.1, 16.0. IR 
(solid, cm-1): 1636, 1490, 1267, 1224, 1156, 1034, 813, 786. API-MS 
(positive) m/z: 226.2 [M+H]+; (negative) m/z: 259.8 [M+Cl]
－
. 
 
(E)-3-methoxy-2-(((2-(methylthio)ethyl)imino)methyl)phenol (L4): A 
mixture of 2-(methylthio)ethan-1-amine (91 mg, 1 mmol) and 2-hydroxy-
6-methoxybenzaldehyde (152 mg, 1 mmol) were refluxed in ethanol (20 
mL) for 16 h. The reaction mixture was then evaporated under vacuum to 
afford a yellow oil. Yield: 214 mg (95%). 1H NMR (400 MHz, CDCl3): δ 
14.29 (s, 1H), 8.83 (s, 1H), 7.22 (t, 1H), 6.54 (d, 1H), 6.30 (d, 1H), 3.84 (s, 
3H), 3.79 (t, 2H), 2.81 (t, 2H), 2.15 (s, 3H). IR (solid, cm-1): 1622, 1463, 
1374, 1246, 1092, 1052, 783, 726. API-MS (positive) m/z: 226.2 [M+H]+. 
 
Cu(L1)(naproxen) (1): Naproxen (69.08 mg, 0.3 mmol) dissolved in 
ethanol (10 mL) was added dropwise under stirring to a mixture of L1 
(67.5 mg, 0.3 mmol) and Cu(NO3)2·3H2O (72 mg, 0.3 mmol) in ethanol 
(10 mL). Triethylamine was added to the mixture to adjust the pH to 7. 
The mixture was refluxed at 80 oC for 24 h. The resulting precipitate was 
filtered off, and the filtrate was evaporated to dryness. The resulting solid 
was washed thoroughly with water and diethyl ether. The product was 
isolated as a green solid (74 mg, 48%). IR (solid, cm-1): 1627, 1603, 1563, 
1469, 1453, 1390, 1301, 1247, 1227, 1214, 1171, 1071, 1029, 927, 855, 
780, 739. HR ESI-MS Calcd. for C25H30CuNO5S [reduced form, M+H]+: 
519.1141 a.m.u. Found [reduced form, M+H]+: 519.0647 a.m.u. Anal. 
Calcd. for 1·2H2O, C25H31CuNO7S: C, 54.29; H, 5.65; N, 2.53. Found: C, 
53.90; H, 5.13; N, 2.92. 
 
Cu(L2)(naproxen) (2): Naproxen (69.08 mg, 0.3 mmol) dissolved in 
ethanol (10 mL) was added dropwise under stirring to a mixture of L2 
(67.5 mg, 0.3 mmol) and Cu(NO3)2·3H2O (72 mg, 0.3 mmol) in ethanol 
(10 mL). Triethylamine was added to the mixture to adjust the pH to 7. 
The mixture was refluxed at 80 oC for 24 h. The resulting precipitate was 
filtered off, and the filtrate was evaporated to dryness. The resulting solid 
was washed thoroughly with water and diethyl ether. The product was 
isolated as a green solid (43 mg, 28%). IR (solid, cm-1): 1606, 1583, 1506, 
1483, 1454, 1397, 1367, 1271, 1232, 1212, 1163, 1033, 928, 899, 855, 
817, 749, 704. HR ESI-MS Calcd. for C25H30CuNO5S [reduced form, 
M+H]+: 519.1141 a.m.u. Found [reduced form,  M+H]+: 519.0680 a.m.u. 
Anal. Calcd. for compound 2, C25H27CuNO5S: C, 58.07; H, 5.26; N, 2.71. 
Found: C, 58.03; H, 5.17; N, 2.83. 
 
Cu(L3)(naproxen) (3): Naproxen (69.08 mg, 0.3 mmol) dissolved in 
ethanol (10 mL) was added dropwise under stirring to a mixture of L3 
(67.5 mg, 0.3 mmol) and Cu(NO3)2·3H2O (72 mg, 0.3 mmol) in ethanol 
(10 mL). Triethylamine was added to the mixture to adjust the pH to 7. 
The mixture was refluxed at 80 oC for 24 h. The resulting precipitate was 
filtered off, and the filtrate was evaporated to dryness. The resulting solid 
was washed thoroughly with water and diethyl ether. The product was 
isolated as a green solid (31 mg, 20%). IR (solid, cm-1): 1633, 1604, 1585, 
1506, 1483, 1457, 1406, 1393, 1366, 1268, 1229, 1213, 1161, 1032, 928, 
853, 809, 749. HR ESI-MS Calcd. for C25H30CuNO5S [reduced form, 
M+H]+: 519.1141 a.m.u. Found [reduced form, M+H]+: 519.0668 a.m.u. 
Anal. Calcd. for compound 3, C25H27CuNO5S: C, 58.07; H, 5.26; N, 2.71. 
Found: C, 58.25; H, 5.14; N, 2.60. 
 
Cu(L4)(naproxen) (4): Naproxen (69.08 mg, 0.3 mmol) dissolved in 
ethanol (10 mL) was added dropwise under stirring to a mixture of L4 
(67.5 mg, 0.3 mmol) and Cu(NO3)2·3H2O (72 mg, 0.3 mmol) in ethanol 
(10 mL). Triethylamine was added to the mixture to adjust the pH to 7. 
The mixture was refluxed at 80 oC for 24 h. The resulting precipitate was 
filtered off, and the filtrate was evaporated to dryness. The resulting solid 
was washed thoroughly with water and diethyl ether. The product was 
isolated as a green solid (104 mg, 67%). IR (solid, cm-1): 1607, 1585, 
1548, 1396, 1363, 1252, 1212, 1105, 1034, 927, 856, 818, 788, 750, 729, 
616, 548. HR ESI-MS Calcd. for C25H30CuNO5S [reduced form, M+H]+: 
519.1141 a.m.u. Found [reduced form, M+H]+: 519.0692 a.m.u. Anal. 
Calcd. for compound 4, C25H27CuNO5S: C, 58.07; H, 5.26; N, 2.71. 
Found: C, 57.95; H, 5.31; N, 2.80. 
 
DNA Cleavage Studies. Plasmid DNA (pUC19) was purchased from 
Invitrogen. The DNA cleavage activity of 1-4 was determined by 
monitoring the conversion of supercoiled plasmid DNA (form I) to nicked 
circular DNA (form II) in Tris-HCl buffer (5 mM, pH 7.4), using agarose-
gel electrophoresis. To probe the effect of compound concentration on 
cleavage, solutions containing DNA (100 ng) and 1-4 (0-50 μM), with a 
total reaction volume of 20 μL, were incubated at 37 oC for 24 h. To 
determine the oxidative cleavage mechanism, solutions containing DNA 
(100 ng), 4 (10 μM), and various radical scavenges (10 mM or 40 mM of 
KI, DMSO, tBuOH, and NaN3), with a total reaction volume of 20 μL, were 
incubated at 37 oC for 24 h. Reactions were also conducted in the 
presence of 10 equivalents of ascorbic acid, and in the presence of 
methyl green (50 µM) and DAPI (50 µM). After incubation, loading buffer 
(5 μL, containing 0.25% bromophenol blue, 0.25% xylene cyanol, and 
60% glycerol) was added and reaction mixtures were immediately loaded 
onto a 1% agarose gel containing ethidium bromide (1.0 mg mL-1). The 
DNA fragments were separated by applying 60 V for 2 h in Tris-acetate 
EDTA (TAE) buffer. The DNA bands were analyzed under UV light using 
a Fujifilm Image Reader LAS-3000. 
 
UV-Vis Tritation Studies.  
To determine the binding constants of 4 with ct-DNA, 4 (50 μM) was 
titrated with concentrated solutions of ct-DNA (mM) in Tris-HCl buffer (5 
mM, pH 7.4). The binding constants were obtained by fitting the data to a 
reciprocal plot of D/Δεap versus D using the following equation: D/Δεap = 
D/Δε - 1/(Δε x K) where the concentration of DNA is expressed in terms 
of base pairs (determined by measuring the absorption at 260 nm and 
the appropriate extinction coefficients), the apparent molar extinction 
coefficient εa = Aobserved/[Complex], Δεap =[εa -εf] and Δε =[εb - εf]. εb is the 
extinction coefficient of the DNA bound complex, and εf is the extinction 
coefficient of the free complex. The UV-Vis spectra were recorded on an 
Agilent Cary100 UV-Vis spectrophotometer. A 1 cm path- length quartz 
cuvette was used to carry out the measurements. 
 
Ethidium Bromide and DAPI Displacement Studies.  
To a mixture of ethidium bromide (1 µM) or DAPI (1 µM) and ct-DNA (20 
µM) in Tris-HCl buffer (5 mM, pH 7.4), an increasing amount 4, L4, or 
naproxen (0-200 µM) was added. The emission spectrum was recorded 
between 550 and 800 nm with an excitation wavelength of 526 nm. The 
fluorescence studies were performed on a Varian Cary Eclipse 
spectrometer. 
 
Measurement of Water-Octanol Partition Coefficient (Log P). The log 
P value for 1-4 was determined using the shake-flask method and UV-Vis 
spectroscopy. The octanol used in this experiment was pre-saturated 
with water. An aqueous solution of 1-4 (500 μL, 100 μM) was incubated 
with octanol (500 μL) in a 1.5 mL tube. The tube was shook at room 
temperature for 48 h. The two phases were separated by centrifugation 
and 1-4 content in each phase was determined by UV-Vis spectroscopy. 
 
Cell Lines and Cell Culture Conditions. The human mammary 
epithelial cell lines, HMLER and HMLER-shEcad were kindly donated by 
Prof. R. A. Weinberg (Whitehead Institute, MIT). HMLER and HMLER-
shEcad cells were maintained in Mammary Epithelial Cell Growth 
Medium (MEGM) with supplements and growth factors (BPE, 
hydrocortisone, hEGF, insulin, and gentamicin/amphotericin-B). The 
GM05757 normal fibroblast cell line was acquired from the American 
Type Culture Collection (ATCC, Manassas, VA, USA) and maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin. The cells were grown 
at 310 K in a humidified atmosphere containing 5% CO2. 
Cytotoxicity MTT assay. The colourimetric MTT assay was used to 
determine the toxicity of 1-4. HMLER, HMLER-shEcad, or GM05757 (5 × 
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103) were seeded in each well of a 96-well plate. After incubating the 
cells overnight, various concentrations of the compounds (0.2-100 µM), 
were added and incubated for 72 h (total volume 200 µL). Stock solutions 
of the compounds were prepared as 10 mM solutions in DMSO and 
diluted using media. The final concentration of DMSO in each well was 
0.5% and this amount was present in the untreated control as well. After 
72 h, 20 μL of a 4 mg/mL solution of MTT in PBS was added to each well, 
and the plate was incubated for an additional 4 h. The MEGM/MTT or 
DMEM/MTT mixture was aspirated and 200 μL of DMSO was added to 
dissolve the resulting purple formazan crystals. The absorbance of the 
solutions in each well was read at 550 nm. Absorbance values were 
normalized to (DMSO-containing) control wells and plotted as 
concentration of test compound versus % cell viability. IC50 and IC20 
values were interpolated from the resulting dose dependent curves. The 
IC50 and IC20 values correspond to the concentration required to 
decrease cell viability by 50 % or 20% and were calculated from dose–
response curves. The reported IC50 values are the average of three 
independent experiments, each consisting of six replicates per 
concentration level (overall n = 18). 
 
Tumorsphere Formation. HMLER-shEcad cells (5 × 103) were plated in 
ultralow-attachment 96-well plates (Corning) and incubated in MEGM 
supplemented with B27 (Invitrogen), 20 ng/mL EGF, and 4 µg/mL 
heparin (Sigma) for 5 days. Studies were conducted in the absence and 
presence of 1-4 and salinomycin. Mammospheres treated with 1-4 and 
salinomycin (at their respective IC20 values, 5 days) were counted and 
imaged using an inverted microscope.  
 
Cellular Uptake. To measure the cellular uptake of 1-4 ca. 1 million 
HMLER-shEcad cells were treated with 1-4 (10 μM) at 37 ºC for 24 h. 
After incubation, the media was removed, the cells were washed with 
PBS (2 mL × 3), harvested, and centrifuged. The cellular pellets were 
dissolved in 65% HNO3 (250 μL) overnight. For 4, cellular pellets were 
also used to determine the copper content in the nuclear and cytoplasmic 
fractions. The Thermo Scientific NE-PER Nuclear and Cytoplasmic 
Extraction Kit were used to extract and separate the nuclear and 
cytoplasmic, fractions. The fractions were dissolved in 65% HNO3 
overnight (250 μL final volume). All samples were diluted 5-fold with 
water and analysed using inductively coupled plasma mass spectrometry 
(ICP-MS, PerkinElmer NexION 350D). Copper levels are expressed as 
Cu (ppb) per million cells. Results are presented as the mean of five 
determinations for each data point. 
 
Intracellular ROS Assay. HMLER-shEcad cells (5 × 103) were seeded 
in each well of a 96-well plate. After incubating the cells overnight, they 
were treated with 4 or H2O2 (50 and 150 µM for 6, 12, and 24 h), in the 
presence or absence of N-acetylcysteine (2.5 mM), and incubated with 6-
carboxy-2′,7′-dichlorodihydrofluorescein diacetate (20 μM) for 30 min. 
The intracellular ROS level was determined by measuring the 
fluorescence of the solutions in each well at 529 nm (λex = 504 nm). 
 
Immunoblotting Analysis. HMLER-shEcad cells (5 x 105 cells) were 
incubated with 4 (5-20 µM for 72 h) at 37 oC. Cells were washed with 
PBS, scraped into SDS-PAGE loading buffer (64 mM Tris-HCl (pH 6.8)/ 
9.6% glycerol/ 2% SDS/ 5% β-mercaptoethanol/ 0.01% Bromophenol 
Blue), and incubated at 95 oC for 10 min. Whole cell lysates were 
resolved by 4-20 % sodium dodecylsulphate polyacylamide gel 
electrophoresis (SDS-PAGE; 200 V for 25 min) followed by electro 
transfer to polyvinylidene difluoride membrane, PVDF (350 mA for 1 h). 
Membranes were blocked in 5% (w/v) non-fat milk in PBST (PBS/0.1% 
Tween 20) and incubated with the appropriate primary antibodies (Cell 
Signalling Technology). After incubation with horseradish peroxidase-
conjugated secondary antibodies (Cell Signalling Technology), immune 
complexes were detected with the ECL detection reagent (BioRad) and 
analysed using a chemiluminescence imager (Amersham Imager 600). 
 
Flow cytometry. HMLER-shEcad cells were seeded in 6-well plates (at 
a density of 5 × 105 cells/ mL) and the cells were allowed to attach 
overnight. The cells were treated with lipopolysaccharide (LPS) (2.5 μM 
for 24 h), and then treated with 4 (12.5-50 μM) or naproxen (20 μM) and 
incubated for a further 48 h. The cells were then harvested by 
trypsinization, fixed with 4% paraformaldehyde (at 37 oC for 10 min), 
permeabilized with ice-cold methanol (for 30 min), and suspended in 
PBS (200 μL). The Alexa Fluor® 488 nm labelled anti-COX-2 antibody (5 
μL) was then added to the cell suspension and incubated in the dark for 1 
hr. The cells were then washed with PBS (1 mL) and analysed using a 
FACSCanto II flow cytometer (BD Biosciences) (10,000 events per 
sample were acquired). The FL1 channel was used to assess COX-2 
expression. Cell populations were analysed using the FlowJo software 
(Tree Star). 
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Figure S1. High resolution ESI-TOF mass spectrum (positive mode) of 1. 
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Figure S2. High resolution ESI-TOF mass spectrum (positive mode) of 2. 
 
 
Figure S3. High resolution ESI-TOF mass spectrum (positive mode) of 3. 
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Figure S4. High resolution ESI-TOF mass spectrum (positive mode) of 4. 
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Figure S5. IR spectrum of (A) 1, (B) 2, (C) 3, and (D) 4 in the solid form.  
 
 
 
 
Figure S6. Concentration-dependent DNA cleavage by 1-3 after a 24 h incubation period. a) Lane 1: 
DNA only; Lane 2-4: DNA + 10, 25, and 50 μM of 1; b) Lane 1: DNA only; Lane 2-4: DNA + 10, 25, 
and 50 μM of 2; c) Lane 1: DNA only; Lane 2-4: DNA + 10, 25, and 50 μM of 3. 
 
 
 
 
Figure S7. Representative reciprocal plot of D/∆εap versus D of 4 (50µM) upon addition of ct-DNA (0 – 
0.9 eq.). 
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Figure S8. Emission spectra for DAPI (1 µM) bound to ct-DNA (20 µM) upon addition of aliquots of 4 
(0-200 µM). 
 
 
Figure S9. Emission spectra for ethidium bromide (1 µM) bound to ct-DNA (20 µM) upon addition of 
aliquots of 4 (0-200 µM). 
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Figure S10. Emission spectra for DAPI (1 µM) bound to ct-DNA (20 µM) upon addition of aliquots of 
naproxen (0-200 µM). 
 
 
Figure S11. Emission spectra for DAPI (1 µM) bound to ct-DNA (20 µM) upon addition of aliquots of 
L4 (0-200 µM). 
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Table S1. Experimentally determined LogP values for 1-4 (mean of three independent experiments ± 
SD). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S12. UV-Vis spectrum of 4 (50 μM) in PBS over the course of 24 h at 37 oC. 
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Figure S13. UV-Vis spectrum of 4 (50 μM) in the presence of ascorbic acid (500 μM) in PBS over the 
course of 24 h at 37 oC. (A) Absorption intensity is shown from 0 - 2.5 a.u. and (B) from 0 - 0.5 a.u for 
clarity.  
 
 
 
 
 
Figure S14. UV-Vis spectrum of 4 (50 μM) in the presence of glutathione (500 μM) in PBS over the 
course of 24 h at 37 oC. 
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Figure S15. UV-vis spectrum of naproxen (50 μM) in PBS at 37 oC. 
 
 
 
Figure S16. UV-Vis spectrum of 4 (250 μM) in the presence of ascorbic acid (2.5 mM) in PBS:DMSO 
(99:1) over the course of 24 h at 37 oC. 
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Figure S17. UV-Vis spectrum of 4 (250 μM) in the presence of glutathione (2.5 mM) in PBS:DMSO 
(99:1) over the course of 24 h at 37 oC. 
 
 
Figure S18. UV-Vis spectrum of 4 (50 μM) in the presence of ascorbic acid (500 μM) and 
bathocuproine disulfonate, BCS (100 μM) in PBS over the course of 24 h at 37 oC. 
 
 
550 600 650 700 750 800
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035 637 nm
A
b
s
o
rp
ti
o
n
 /
 a
.u
.
Wavelength / nm
 4
 + GSH 3 h
 + GSH 16 h
 + GSH 24 h
400 450 500 550 600 650 700 750 800
0.0
0.1
0.2
0.3
0.4
0.5
480 nm
480 nm
A
b
s
o
rp
ti
o
n
 /
 a
.u
.
Wavelength / nm
 [Cu
I
(BCS)
2
]
3-
 4
 +ASC +BCS 0 h
 +ASC +BCS 3 h
 +ASC +BCS 16 h
 +ASC +BCS 24 h
FULL PAPER          
 
 
 
 
 
Figure S19. UV-Vis spectrum of 4 (50 μM) in the presence of glutathione (500 μM) and bathocuproine 
disulfonate, BCS (100 μM) in PBS over the course of 24 h at 37 oC. 
 
Figure S20. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad 
cells with 1 after 72 h incubation. 
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Figure S21. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad 
cells with 2 after 72 h incubation. 
 
  
Figure S22. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad 
cells with 3 after 72 h incubation. 
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Figure S23. Representative dose-response curves for the treatment of HMLER and HMLER-shEcad 
cells with 4 after 72 h incubation. 
 
 
Figure S24. Representative dose-response curves for the treatment of GM05757 cells with 1-4 after 72 
h incubation. 
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Table S2. IC50 values of the copper(II) complexes, 1-4 against GM05757 cells. Determined after 72 h 
incubation (mean of three independent experiments ± SD).  
 
 
 
 
 
 
 
 
 
 
Figure S25. Copper content in HMLER-shEcad cells treated with 1-4 (10 μM for 24 h). 
 
 
Cu(II) complex GMO5757 IC50 [μM] 
1 29.7 ± 2.9  
2 33.8 ± 4.7 
3 62.6 ± 0.6 
4 71.1 ± 1.1 
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Figure S26. Normalised ROS activity in untreated HMLER-shEcad cells (control) and HMLER-shEcad 
cells treated with 4 (50 µM for 6, 12, and 24 h) and co-treated with 4 (50 µM for 6, 12, and 24 h) and N-
acetylcysteine (2.5 mM for 6, 12, and 24 h). Error bars represent standard deviations and Student t test, 
* = p < 0.05. 
 
 
Figure S27. Normalised ROS activity in untreated HMLER-shEcad cells (control) and HMLER-shEcad 
cells treated with H2O2 (150 µM for 6, 12, and 24 h) and co-treated with H2O2 (150 µM for 6, 12, and 
24 h) and N-acetylcysteine (2.5 mM for 6, 12, and 24 h). Error bars represent standard deviations and 
Student t test, ** = p < 0.01. 
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Figure S28. Immunoblotting analysis of proteins related to the DNA damage and apoptosis pathways. 
Protein expression in HMLER-shEcad cells following treatment with 4 (5, 10, and 20 μM) after 72 h 
incubation. Whole cell lysates were resolved by SDS-PAGE and analyzed by immunoblotting against 
γH2AX, phos-CHK2, cleaved caspase 7, cleaved caspase 3, and β-actin (loading control). 
 
 
Figure S29. Representative histograms displaying the green fluorescence emitted by anti-COX-2 Alexa 
Fluor 488 nm antibody-stained HMLER-shEcad cells treated with LPS (2.5 μM) for 24 h (red) followed 
by 48 h in media containing naproxen (20 μM, blue). 
 
 
 
